Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Rogers, Thomas F., Zhao, Fangzhu, Huang, Deli, Beutler, Nathan, Burns, Alison, He, Wan-ting, Limbo, Oliver, Smith, Chloe +26 more·2020·Science
DOI 10.1126/science.abc7520

Cited by (1,034)

Items 901–1,000 of 1,034

  1. A design strategy to generate a SARS‐CoV‐2 RBD vaccine that abrogates ACE2 binding and improves neutralizing antibody responses
    C. Ratswohl, Clara Vázquez García, A. Ahmad, Hannes Gonschior, M. Lebedin, Casper Silvis, Lisa Spatt, Cathrin Gerhard, Martin Lehmann, L. Sander et al. · 2023 · European Journal of Immunology
  2. Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron
    Jakob Kreye, S. Momsen Reincke, Stefan Edelburg, Lara Maria Jeworowski, Hans‐Christian Kornau, Jakob Trimpert, Peter Hombach, Sophia Halbe, Volker Nölle, Martin Meyer et al. · 2023 · iScience
  3. Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19
    Elizabeth E. Zumbrun, C. Kaku, L. Dillinger, Samantha E. Zak, Ana I. Kuehne, Russell R. Bakken, J. Koehler, K. Delp, Christopher P. Stefan, Raina Kumar et al. · 2022 · Antimicrobial Agents and Chemotherapy
  4. HIV and SARS-CoV-2 Co-Infection: From Population Study Evidence to In Vitro Studies
    Chiara Stefani, Tobia Fantoni, Michele Bissoli, Jordan Thomas, A. Ruggiero · 2022 · Life
  5. SARS-CoV-2 ORF8 limits expression levels of Spike antigen
    Ikjung Kim, Yong-ho Lee, M. Khalid, Yi-Ni Zhang, M. Ott, E. Verdin · 2022 · bioRxiv
  6. Building a Resilient Scientific Network for COVID-19 and Beyond
    N. Babady, R. M. Burckhardt, F. Krammer, P. Moore, L. Enquist · 2022 · mBio
  7. The diversity of the glycan shield of sarbecoviruses closely related to SARS-CoV-2
    J. Allen, Dylan Ivory, Sophie Ge Song, Wan-ting He, Tazio Capozzola, Peter Yong, D. Burton, R. Andrabi, M. Crispin · 2022 · bioRxiv
  8. Nasal Mucosa Exploited by SARS-CoV-2 for Replicating and Shedding during Reinfection
    Heng Li, Xin Zhao, Jing Li, Hui-Wen Zheng, Yu-Rong Zhao, Jin-Ling Yang, Jing-Xian Zhou, Fengmei Yang, Yan-Li Chen, Yuanyuan Zuo et al. · 2022 · Viruses
  9. The evolution of SARS-CoV-2 variants and their clinical and healthcare implications
    J. M. Eiros, M. Hernández · 2022 · Revista clínica española (Ed. impresa)
  10. The Impact of Covid-19 Pandemic on Women Entrepreneurs: An Analysis from Socio-Economic Perspective in Rangpur City Corporation, Bangladesh
    Md. Abdul Monnaf, Marufa Rahman · 2022 · Global Journal of Human-Social Science Research
  11. Evidence for a Potential Pre-Pandemic SARS-like Coronavirus Among Animals in North America
    T. Hancock, Peyton Hickman, Niloo Kazerooni, M. Kennedy, S. Kania, M. Dennis, Nicole Szafranski, R. Gerhold, C. Su, Tom J. Masi et al. · 2021 · bioRxiv
  12. Viral population genomics reveals host and infectivity impact on SARS-CoV-2 adaptive landscape
    K. Gayvert, R. Copin, S. McKay, Ian Setliff, W. Lim, A. Baum, C. Kyratsous, G. Atwal · 2021 · bioRxiv
  13. Severe Acute Respiratory Syndrome Coronavirus 2 Antigens as Targets of Antibody Responses
    Alana F. Ogata, Roey Lazarovits, Augusta Uwamanzu‐Nna, Tal Gilboa, Chi‐An Cheng, David R. Walt · 2021 · Clinics in Laboratory Medicine
  14. Study of Riamilovir Activity Against SARS-CoV-2 Infection In Syrian Hamsters
    S. Chepur, A. V. Smirnova, A. Kirienko, I. Myasnikova, B. A. Kanevsky, P. V. Sorokin · 2021 · Antibiotics and Chemotherapy
  15. Differential Antibody Response to SARS-CoV-2 Antigens in Recovered and Deceased Iranian COVID-19 Patients
    Faezeh Maghsood, Danesh Hassani, V. Salimi, G. Kardar, J. Khoshnoodi, A. Ghaderi, Seyyed Reza Raeeskarami, Abdorrahman Rostamian, M. S. Seyyedsalehi, Raoufeh Ahmadi Fesharaki et al. · 2021 · Viral immunology
  16. Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain
    G. Cerutti, Yi-Cheng Guo, Pengfei Wang, M. Nair, Yao-Xing Huang, J. Yu, Li-Hong Liu, P. Katsamba, F. Bahna, E. Reddem et al. · 2021 · bioRxiv
  17. The impact of high-resolution structural data on stemming the COVID-19 pandemic
    R. Cox, Richard K. Plemper · 2021 · Current Opinion in Virology
  18. Quantatitive Analysis of Conserved Sites on the SARS-CoV-2 Receptor-Binding Domain to Promote Development of Universal SARS-Like Coronavirus Vaccines
    Si-Ling Wang, Ding-Hui Wu, Hua-long Xiong, Juan Wang, Zimin Tang, Zi-Hao Chen, Yi-Zhe Wang, Ya-Li Zhang, Dong Ying, Xuansheng Lin et al. · 2021 · bioRxiv
  19. All‐Atom Simulations and Free‐Energy Calculations of Antibodies Bound to the Spike Protein of SARS‐CoV‐2: The Binding Strength and Multivalent Hydrogen‐Bond Interactions
    Hwankyu Lee · 2021 · Advanced Theory and Simulations
  20. Lasting memories of SARS-CoV-2 infection
    Maya M.L. Poon, Donna L. Färber · 2021 · The Journal of Experimental Medicine
  21. Insights into biological therapeutic strategies for COVID-19
    Xiaolong Tian, Cheng Li, Yan-Ling Wu, T. Ying · 2021 · Fundamental Research
  22. Selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants
    Fatai S. Oladunni, Jun-Gyu Park, Kevin Chiem, Cheng-Jin Ye, Michael Pipenbrink, M. Walter, J. Kobie, L. Martínez-Sobrido · 2021 · Journal of Virological Methods
  23. A Label-Free SARS-CoV-2 Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients
    Yi-Qi R. Luo, C. Yun, I. Chakraborty, Alan H. B. Wu, K. Lynch · 2021 · medRxiv
  24. Narrative review of the novel coronavirus SARS-CoV-2: update on genomic characteristics, transmissions and animal model
    Zhao-Yong Zhang, Lu Zhang, Ai-Ru Zhu, Yan-Qun Wang, Wen-Da Guan, Zhi-Qi Zeng, Jing Sun, Fang Li, Jing-Xian Zhao, Zi-Feng Yang et al. · 2020 · Journal of Thoracic Disease
  25. Heterologous betacoronavirus spike immunization in non-human primates elicits antibodies that neutralize both sarbeco- and merbecoviruses.
    K. Dueker, Tazio Capozzola, Zi-Qi Feng, Ryan N. Lin, Jonathan Hurtado, S. Bangaru, Meng Yuan, N. Beutler, Elijah Garcia, Wan-ting He et al. · 2026 · Cell Reports
  26. Antibody Transcytosis and Neutralizing Activity in Respiratory Epithelial Cells
    Eduardo U. Anaya, Yee Vue, Maggie Li, Jessica D. Resnick, Nico J. Swanson, D. Sullivan, A. Pekosz · 2026 · bioRxiv
  27. Proof-of-concept of targeted degradation of p38α/β MAPK host-kinase as a potent inhibitor of coronaviruses
    Gemma Cooper, T. Snape, M. Shivkumar · 2026 · bioRxiv
  28. Immune-focused RBD nanoparticles induce cross-reactive, RBS-directed responses capable of variant-resistant SARS-CoV-2 neutralization
    Kylie M. Konrath, Kevin Liaw, Nicholas J. Tursi, Madison E. McCanna, B. Warner, E. Gary, Xi-Zhou Zhu, Cory Livingston, Cara Monastra, D. Frase et al. · 2026 · PLoS Pathogens
  29. Integrated humoral and inflammatory signatures predict outcomes in severe COVID‐19: a 14‐day longitudinal analysis
    H. N. Ibiapina, F. Magalhães-Gama, Juliana Costa Ferreira Neves, Fabíola Silva Alves-Hana, I. Costa-Rocha, Alice Aparecida Lourenço, Á. L. Ribeiro, G. Ferreira, Thais F. C. Fraga-Silva, A. A. Paim et al. · 2026 · Clinical & Translational Immunology
  30. Long-Term Protective Immune Responses Induced by rBCG-RBD/rRBD Heterologous Prime/Boost Immunization Strategy: Fusion of RBD-Wuhan with LTB Adjuvant Induces Cross-Reactivity with SARS-CoV-2 Variant Omicron
    G. Gaboardi, M. Trentini, A. I. Kanno, Luana Moraes, A. D. Januzzi, L. R. Pereira, G. Dias, L. Huergo, Sergio C. Oliveira, A. Báfica et al. · 2026 · Vaccines
  31. An RGD motif on SARS-CoV-2 Spike induces TGF-β signaling and downregulates interferon
    Nicholas Peter Gracie, Anupriya Aggarwal, Rachel Luo, Mitchell Spicer, Sobia Idrees, Caroline L. Ashley, Sibel Alca, Timothy Ison, Megan C. Steain, Karishma Patel et al. · 2025 · Journal of Virology
  32. Affinity Maturation and Light-Chain-Mediated Paratope Diversification Anticipate Viral Evolution
    John Dingus, Duck Kyun Yoo, Sachin Kumar, Yajuan Wang, Md Golam Kibria, Shahab Saghei, Zahra Allahyari, J. Chen, Natalie Caputo, Jason Hwang et al. · 2025 · bioRxiv
  33. Structure-guided bispecific antibody engineering confers broad protection against KP.3.1.1 and sarbecoviruses
    Yun-Ping Ma, Qian-Ying Liu, Palizhati Rehati, Zhao-Yong Zhang, Ying-Dan Wang, Zhi-Min Liu, Jiali Chen, Xuezhou Bai, Aihua Hao, Yan-Qun Wang et al. · 2025 · iScience
  34. LL‐37 Inhibits TMPRSS2‐Mediated S2' Site Cleavage and SARS‐CoV‐2 Infection but Not Omicron Variants
    Zhen-Fei Bi, Wen-Hui Ren, Hao Zeng, Yuan-Yuan Zhou, Jian Liu, Zi-Min Chen, Xindan Zhang, Xue-Mei He, Guang-Wen Lu, Yu-Quan Wei et al. · 2025 · Cell Proliferation
  35. In-house assays for detecting anti-SARS-CoV-2 antibodies in serum and urine: Correlation with COVID-19 severity from a cohort study in Qatar.
    N. Vaikath, M. Al-Nesf, N. Majbour, Houari B. Abdesselem, Vijay Gupta, Ilham Bensmail, Ilham Y. Abdi, K. A. Elmagarmid, Shadah Shabani, Indulekha P Sudhakaran et al. · 2025 · Journal of Infection and Public Health
  36. Investigating SARS-CoV-2 Neutralising Antibody Response in Sheep
    Milena Samojlović, J. R. Mesquita, Sérgio Santos-Silva, Malin Neptin, J. Esbjörnsson · 2024 · Microorganisms
  37. Evaluation of a surrogate virus neutralization assay for detecting neutralizing antibodies against SARS-CoV-2 in an African population
    Lilian Nkinda, Victoria Shayo, Salim S. Masoud, Godfrey Barabona, I. Ngare, Ponsian P Kunambi, Emmanuel Nkuwi, D. Kamori, F. Msafiri, E. Osati et al. · 2024 · Biology Methods and Protocols
  38. Production of a monoclonal antibody targeting the SARS-CoV-2 Omicron spike protein and analysis of SARS-CoV-2 Omicron mutations related to monoclonal antibody resistance.
    Jinsoo Kim, Suyeon Kim, Sangkyu Park, Dongbum Kim, Minyoung Kim, Kyeongbin Baek, BoKyu Kang, Ha-Eun Shin, Myeong-Heon Lee, Younghee Lee et al. · 2024 · Microbes and infection
  39. Chemical Proteomics Approaches for Screening Small Molecule Inhibitors Covalently Binding to SARS‐Cov‐2
    Liu-hai Zheng, Qian Zhang, Piao Luo, Fei Shi, Ying Zhang, Xiao-Xue He, Ye-Hai An, Guangqing Cheng, Xiaoya Pan, Zhijie Li et al. · 2024 · Advances in Biology
  40. SARS-CoV-2 neutralization and protection of hamsters via nasal administration of a humanized neutralizing antibody
    Lebedin, Mikhail, Petrovsky, Nikolai, Tabynov, Kairat, Tabynov, Kaissar, Lebedin, Yuri · 2024
  41. A Longitudinal Study in Tunisia to Assess the Anti-RBD IgG and IgA Responses Induced by Three Different COVID-19 Vaccine Platforms
    Wafa Ben Hamouda, Mariem Hanachi, S. Ben Hamouda, Wafa Kammoun Rebai, A. Gharbi, Amor Baccouche, J. Bettaieb, Oussema Souiai, M. Barbouche, K. Dellagi et al. · 2024 · Tropical Medicine and Infectious Disease
  42. A magnetic-enhanced FRET biosensor for simultaneous detection of multiple antibodies
    Li-Hua Li, Yao Lu, Xin-xin Lao, Sin-Yi Pang, Menglin Song, Man-Chung Wong, Feng Wang, Mo Yang, Jian-Hua Hao · 2024 · Smart Materials in Medicine
  43. Dissecting the impact of somatic hypermutation on SARS-CoV-2 neutralization and viral escape
    M. Korenkov, Matthias Zehner, H. Cohen-Dvashi, A. Borenstein-Katz, Lisa Kottege, H. Janicki, K. Vanshylla, Timm Weber, H. Gruell, M. Koch et al. · 2023 · bioRxiv
  44. “Broad-Spectrum Heavily Mutated Monoclonal Antibody Isolated from COVID-19 Convalescent Vaccinee with Capacity to Neutralize SARS-CoV2 Variants Ranging from B.1 to BQ.1.1.”
    A. Choudhary, D. Calianese, W. Honnen, Afsal Kolloli, R. Dikdan, D. Jaijyan, G. Song, Tazio Capozzola, Chandler B Sy, Vikash Akkaraju et al. · 2023 · bioRxiv
  45. Benchmarking cassette-based deep mutagenesis by Golden Gate assembly
    Nicolas Daffern, I. Francino-Urdaniz, Z. Baumer, T. Whitehead · 2023 · bioRxiv
  46. Broad and potent neutralizing mAbs are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection
    J. Seow, Z. A. Shalim, C. Graham, Simon Kimuda, Aswin Pillai, T. Lechmere, Ashwini Kurshan, Atika M. Khimji, L. Snell, G. Nebbia et al. · 2023 · bioRxiv
  47. Lessons learned: A look back at the performance of nine COVID-19 serologic assays and their proposed utility
    Nicole V. Tolan, Mia S. DeSimone, M. Fernandes, Joshua E. Lewis, D. Simmons, P. Schur, M. Brigl, M. Tanasijevic, M. Desjardins, A. Sherman et al. · 2023 · Clinical Biochemistry
  48. Assessing the long-stand antibody response induced by COVID-19 vaccines: A study in an educational cohort in San Luis, Argentina
    R. J. Eliçabe, Matías Nicolás Distel, B. Jofré, Marianela Leporati, J. E. Silva, J. Arias, C. Gorlino, S. Funes, Marisol Velazquez, Patricia Vitale et al. · 2022 · Vaccine
  49. Angiotensin Converting Enzyme 2 (ACE2) - A macromolecule and its impact on human reproduction during COVID-19 pandemic
    G. G, Vickram A. S., K. Dhama · 2022 · Journal of Experimental Biology and Agricultural Sciences
  50. Pandemic’s silver lining
    F. Ferrara, S. D'Angelo, M. F. Erasmus, Andre A. R. Teixeira, Camila Leal-Lopes, L. P. Spector, Tom Pohl, A. Fanni, S. Cocklin, A. Bradbury · 2022 · mAbs
  51. Antibody Therapy for COVID-19: Categories, Pros, and Cons
    Hadi Zare Marzouni, M. Rahbar, N. Seddighi, Mohsen Nabizadeh, Sepideh Meidaninikjeh, Nasim Sabouni · 2022 · Viral immunology
  52. Epitopes mapped onto SARS-CoV-2 receptor-binding motif by five distinct human neutralising antibodies
    Lucas J. Gutiérrez, Rodrigo D. Tosso, M. N. C. Zarycz, R. Enriz, H. Baldoni · 2022 · Molecular Simulation
  53. Potential of antibody pair targeting conserved antigenic sites in diagnosis of SARS-CoV-2 variants infection
    Si-Ling Wang, Yang Wu, Yi-Zhe Wang, Zi-Hao Chen, Dong Ying, Xue Lin, Chang Liu, Min Lin, Jin-Lei Zhang, Yuhe Zhu et al. · 2022 · Journal of Virological Methods
  54. A one-year follow-up study on dynamic changes of leukocyte subsets and virus-specific antibodies of patients with COVID-19 in Sichuan, China
    Ren-Jie Xu, Ben-Nan Zhao, Li-Juan Lan, Ya-Ling Liu, Ya-Lun Li, Liang-Shuang Jiang, Shui-Ping Dai · 2022 · International Journal of Medical Sciences
  55. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19
    Caroline Hirsch, Yun Soo Park, Vanessa Piechotta, Khai Li Chai, Lise J Estcourt, Ina Monsef, Susanne Salomon, Erica M. Wood, Cynthia So‐Osman, Zoe McQuilten et al. · 2022 · Cochrane Database of Systematic Reviews
  56. Targeted protein S-nitrosylation of ACE2 as potential treatment to prevent spread of SARS-CoV-2 infection
    Chang-ki Oh, Tomohiro Nakamura, N. Beutler, Xu Zhang, J. Piña-Crespo, M. Talantova, S. Ghatak, D. Trudler, Lauren N. Carnevale, S. Mckercher et al. · 2022 · bioRxiv
  57. A Feasible Alternative Strategy Targeting Furin Disrupts SARS-CoV-2 Infection Cycle
    T. Mondal, Gururaj Shivange, Alaa Habieb, Jogender Tushir-Singh · 2022 · Microbiology spectrum
  58. Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability
    Wei Shi, Ling-Shu Wang, T. Zhou, M. Sastry, E. Yang, Yi Zhang, Man Chen, Xuejun Chen, M. Choe, A. Creanga et al. · 2022 · bioRxiv
  59. Animal Models of Human Pathology 2020
    M. Fedele, O. Gualillo, A. Vecchione · 2022 · BioMed Research International
  60. A bivalent EBV vaccine induces neutralizing antibodies that block B and epithelial cell infection and confer immunity in humanized mice
    Chih-Jen Wei, Wei Bu, L. Nguyen, J. Batchelor, JungHyun Kim, S. Pittaluga, J. Fuller, Hanh Nguyen, Te-Hui Chou, Jeffrey W. Cohen et al. · 2022 · bioRxiv
  61. Contribution of endogenous and exogenous antibodies to clearance of SARS-CoV-2 during convalescent plasma therapy
    M. Marconato, I. Abela, Anthony Hauser, Magdalena Schwarzmüller, Rheliana Katzensteiner, D. Braun, Selina Epp, A. Audigé, J. Weber, P. Rusert et al. · 2021 · medRxiv
  62. Preclinical Immunological Evaluation of an Intradermally Administered Heterologous Vaccine Against SARS-CoV-2 Variants
    Qi-Han Li, Sheng-Tao Fan, K. Xiao, Dan-Dan Li, Heng Zhao, Jingjing Zhang, Li Yu, Penglan Chang, Shuang-Li Zhu, Xing-Li Xu et al. · 2021
  63. A practical approach to SARS-CoV-2 testing in a pre and post-vaccination era
    Sean C. Taylor · 2021 · Journal of Clinical Virology Plus
  64. A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in rhesus macaques
    Ronald R. Cobb, Joseph P. Nkolola, P. Gilchuk, A. Chandrashekar, R. V. House, Christopher G. Earnhart, N. Dorsey, Svetlana A. Hopkins, Doris M. Snow, Rita E. Chen et al. · 2021 · bioRxiv
  65. Interplay between receptor binding, immune escape and protein stability determines the natural selection of SARS-CoV-2 variants
    V. Upadhyay, A. Lucas, Sudipta Panja, Ryuki Miyauchi, Krishna M. G. Mallela · 2021
  66. [Susceptibility of animal species to experimental SARS-CoV-2 (Coronaviridae: Coronavirinae: Betacoronavirus; Sarbecovirus) infection].
    N. Petrova, K. Ganina, S. Tarasov · 2021 · Voprosy virusologii
  67. Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drive rapid and potent immunogenicity capable of single-dose protection
    Kylie M. Konrath, Kevin Liaw, Yuan-Han Wu, Xi-Zhou Zhu, Susanne N. Walker, Ziyang Xu, K. Schultheis, Neethu Chokkalingam, Jianqiu Du, Nicholas J. Tursi et al. · 2021 · bioRxiv
  68. Coronavirus Disease 19 and Future Ecological Crises: Hopes from Epigenomics and Unraveling Genome Regulation in Humans and Infectious Agents
    K. Dzobo · 2021 · Omics
  69. Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following induction
    J. Haydu, Yael Flamand, R. Vedula, J. Versluis, Anne Charles, Kevin M. Copson, R. Stone, D. DeAngelo, D. Neuberg, R. C. Lindsley et al. · 2021 · American journal of hematology/oncology
  70. Structure-based Design of a Specific, Homogeneous Luminescence Enzyme Reporter Assay for SARS-CoV-2
    Frederic A. Fellouse, Shane Miersch, Chao Chen, S. Michnick · 2021 · Journal of Molecular Biology
  71. Application of a Method for Engineering Multivalent Antibodies to Substantially Enhance Functional affinity of Clinical Trial Anti-SARS-CoV-2 Antibodies
    A. Leach, A. Miller, E. Bentley, G. Mattiuzzo, Jemima C. Thomas, C. McAndrew, R. van Montfort, T. Rabbitts · 2021 · Research Square
  72. Adaptive immune responses to SARS-CoV-2
    Donald N. Forthal · 2021 · Advanced Drug Delivery Reviews
  73. A Recombinant Protein SARS-CoV-2 Candidate Vaccine Elicits High-titer Neutralizing Antibodies in Macaques.
    G. Baisa, David Rancour, K. Mansfield, Monika Burns, Lori Martin, D. Cunha, J. Fischer, Frauke Muecksch, T. Hatziioannou, P. Bieniasz et al. · 2021 · Research Square
  74. SARS-CoV-2 Cellular Infection and Therapeutic Opportunities: Lessons Learned from Ebola Virus
    J. Muñoz-Basagoiti, D. Perez-Zsolt, J. Carrillo, J. Blanco, B. Clotet, N. Izquierdo-Useros · 2021 · Membranes
  75. MHC-II constrains the natural neutralizing antibody response to the SARS-CoV-2 spike RBM in humans
    Andrea Castro, Kivilcim Ozturk, M. Zanetti, H. Carter · 2020 · bioRxiv
  76. Anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) potency of Mefloquine as an entry inhibitor in vitro
    Kaho Shionoya, Masako Yamasaki, Shoya Iwanami, Yusuke Ito, S. Fukushi, Hirofumi Ohashi, Wakana Saso, Tomohiro Tanaka, S. Aoki, Kouji Kuramochi et al. · 2020 · bioRxiv
  77. Peiyuan xuanhua jiedu decoction potentiates SARS-CoV-2 vaccine-induced immunity via STAT3-dependent Tfh cell differentiation
    Xue-Yan Wang, Xiao-Ying Xu, Xia-Feng Zhang, Jian-Hong Qian, F. A. A. Majid, Ming-Qian Zhou, Cheng-Ping Wen · 2026 · Clinical Traditional Medicine and Pharmacology
  78. Multifunctional antibody responses from a primate Shigella outbreak inform vaccine design
    Robert M. Gallant, Paul Savarino, Sophia Pulido, Morgan S. A. Gilman, T. Lu, Jennifer M. Hayes, Nicholas L. Xerri, Torrey Williams, M. A. Ochoa, Zackary Dietz et al. · 2026 · Science Translational Medicine
  79. Rapid discovery of monoclonal antibodies via high-throughput single BCR affinity sequencing
    Mengzhu Hu, Qiu-Yu Lian, Xiaonan Cui, Xiao Chen, Xue Dong, Mengge Huang, Guang-Chao Wang, Yan Hu, Hao Zhang, Jia-Can Su et al. · 2026 · Nucleic Acids Research
  80. ACE2 decoy Fc-fusions and bispecific killer engagers require Fc engagement for in vivo efficacy against SARS-CoV-2.
    Jenna K. Dick, V. Krishna, D. Hicks, Jules A. Sangala, Robert J. Oldham, Benjamin T. Zandstra, C. Baehr, J. Verbeek, M. Cragg, M. Pravetoni et al. · 2026 · Journal of Immunology
  81. Multiparatopic antibodies overcome tyrosine kinase inhibitor resistance by inducing lysosomal degradation of EGFR mutants
    Chun-Jie Lin, Jie Liu, Jia-Cheng Ni, Ding-Rui Chen, Ya-Fei Liu, Wan Zhu, Yi Sheng, Yunling Wang, Yingbin Gao, Si-E Zhang et al. · 2026 · Oncogene
  82. Somatic Evolution of a Germline Antibody Expands its Breadth to Neutralize Early SARS‐CoV‐2 Omicron Variants
    Huibin Lv, Ziqi Feng, Qi Wen Teo, Chunke Chen, Akshita Baiju Gopal, Danbi Choi, Timothy J.C. Tan, Yun Sang Tang, Lewis Yu-Lam Siu, Armita Nourmohammad et al. · 2026 · Advanced Science
  83. Development of anti-IgA monoclonal and polyclonal reagents for detecting mucosal and systemic IgA in nonhuman primates.
    Yasmine Iacone, Joanna Zikos, David H. Foehl, P. Katyal, Vimala Gollamudi, L. Bibb, Diogo Magnani · 2026 · JIM - Journal of Immunological Methods
  84. In vivo evolution of antibody CR3022 expands cross-neutralization of SARS-CoV-2 variants and informs pan-sarbecovirus immunity.
    Yan-Bin Fu, Zi-Qi Feng, S. Erickson, P. Halfmann, Lei Li, Jordan C. Chervin, Chloe A. Troxell, Jiayi Sun, A. Yasuhara, S. Changrob et al. · 2026 · Cell Reports
  85. Mining antibody functionality via AI-guided structural landscape profiling
    S. Terekhov, N. Ivanisenko, Nan Zhang, Y. Mokrushina, D. Nolde, Y. Lomakin, A. Zalevsky, L. A. Ovchinnikova, D. Malabuiok, M. Baranova et al. · 2026 · Nature Communications
  86. Exploring the diverse binding ability of SARS-CoV-2 variant RBDs to different antibody classes: a computational study
    Hoang Linh Nguyen, T. Nguyen, Linh Tran, Mai-Suan Li · 2026 · RSC Advances
  87. A Modular Vaccine Platform Against SARS‐CoV‐2 Based on Self‐Assembled Protein Nanoparticles
    Seojung Lee, Y. Jang, Yujin Kim, Yu-Mi Shin, Ji-Joon Song, Meehyein Kim, Sangyong Jon · 2026 · Advancement of science
  88. Structural Adaptability of IgA and IgM Supports Broad SARS‐CoV‐2 Variant Neutralization
    Yalcin Pisil, Hisatoshi Shida, Sandra Morales Ruiz, K. Cho, M. Güngör, Z. Yazıcı, Tomoyuki Miura · 2026 · Journal of Medical Virology
  89. A Chip‐Based Surveillance Platform for Detecting Antibody‐Based Immunity and Immune Escape Using SARS‐CoV‐2 Pseudovirus Surrogates
    Maisha M. Feroz, Seok‐Joon Kwon, Katherin Berman, Nicholas John Mantis, Jonathan S. Dordick · 2025 · Biotechnology and Bioengineering
  90. Two cross-neutralizing antibodies isolated from a COVID-19 convalescent via single B cell sorting
    Yuan-Yuan Hu, Cai-Qin Hu, Jun-Wei Su, Biao Zhu, Hao Liang, Yi-Ming Shao · 2025 · Archives of Virology
  91. Development of a Thermostable and Broadly Neutralizing Pan-Sarbecovirus Vaccine Candidate
    Simran Srivastava, Sahil Kumar, Suman Mishra, Raju S. Rajmani, Randhir Singh, S. Dutta, R. Ringe, Raghavan Varadarajan · 2025 · bioRxiv
  92. Post-transfusion activation of coagulation pathways during severe COVID-19 correlates with COVID-19 convalescent plasma antibody profiles
    S. Weiss, Hung-Mo Lin, Eric Acosta, N. Komarova, Ping Chen, Dominik Wodarz, Ian Baine, R. Duerr, A. Wajnberg, A. Gervais et al. · 2025 · Journal of Clinical Investigation
  93. Humoral immune response to SARS-CoV-2 vaccines in patients with autoimmune rheumatic diseases.
    P. M. Corbalan, R. Tomas-Grau, M. Pera, D. Ploper, G. V. Espasa, S. Cazorla, María Lilia Leguizamón, E. V. Pingitore, A. Barbaglia, C. Maldonado-Galdeano et al. · 2025 · Archives of Medical Research
  94. Role of gamma irradiation and disaccharide trehalose to induce immune responses in Syrian hamster model against Iranian SARS-CoV-2 virus isolate
    F. Motamedi-Sedeh, A. Khorasani, Mohsen Lotfi, S. M. Moosavi, Arash Arbabi, S. Hosseini · 2024 · Veterinary Research Forum
  95. Navigating the Dynamic Landscape of SARS-CoV-2: The Dual Role of Neutralizing Antibodies, Variability in Responses, and Strategies for Adaptive Pandemic Control
    Venkatesh Anand Iyer, Aditi Mohan, Dharmender Kumar, Praveen Dahiya · 2024 · COVID
  96. N121T and N121S substitutions on the SARS‐CoV‐2 spike protein impact on serum neutralization
    Van Thi Lo, Hyun A. Lim, Seong Sik Jang, Min Chan Kim, Alain Chrysler Chamfort, Ha Yeon Kim, Da-Young Mun, Min-Chang Kang, Han Byul Lee, Sunjoo Kim et al. · 2024 · Journal of Medical Virology
  97. ONE HEALTH APPROACH ON SARS-COV-2 – USING SHEEP AS SENTINEL ANIMALS TO INCREASE FUTURE PANDEMIC PREPAREDNESS – a pilot study
    Milena Samojlović, J. Mesquita, Sérgio Santos-Silva, Malin Neptin, J. Esbjörnsson · 2024 · bioRxiv
  98. Development and validation of a prediction score for failure to casirivimab/imdevimab in hospitalized patients with COVID-19 pneumonia
    Alessandro Cozzi‐Lepri, Vanni Borghi, Salvatore Rotundo, B Mariani, Anna Maria Ferrari, Cosmo Del Borgo, Francesca Bai, Pietro Colletti, Piermauro Miraglia, Carlo Torti et al. · 2024 · Frontiers in Medicine
  99. Potential Protectivity of a Conjugated COVID-19 Vaccine against Tetanus
    D. Doroud, Fatemeh Ashrafian, Amir Javadi, S. Dahmardeh, M. Banifazl, Anahita Bavand, Mona Sadat Larijani, Amitis Ramezani · 2024 · Vaccines
  100. Monoglycosylated SARS-CoV-2 receptor binding domain fused with HAstem-scaffolded protein vaccine confers broad protective immunity against SARS-CoV-2 and influenza viruses
    Chia-Ying Wu, Yung-Chieh Tseng, Shao-En Kao, Liyang Wu, Jen-Tzu Hou, Yu‐Chih Yang, Pei‐Wen Hsiao, Juine-Ruey Chen · 2023 · Antiviral Research